Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanubrutinib + R-ICE
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Zanubrutinib + R-ICE is a combination therapy regimen that combines the BTK inhibitor zanubrutinib with the standard salvage chemotherapy regimen R-ICE (rituximab, ifosfamide, carboplatin, and etoposide). This regimen is primarily used for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL), particularly in specific genetic subtypes such as MCD and BN2. Clinical studies have shown promising efficacy with overall response rates of 80-84% and complete response rates of approximately 60%. The combination has demonstrated a favorable safety profile compared to other BTK inhibitor combinations, with manageable hematological toxicities.
02
Targets
Beyond the preview
Go deeper on zanubrutinib + R-ICE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanubrutinib + R-ICE.